Such therapies include cancer vaccines (Melief et al., 2015), immune agonists such as anti-CD40 (Beatty et al., 2017), and inhibitors of immune checkpoints such as anti-CTLA-4 (Leach et al., 1996) and anti-PD-1/PD-L1(Iwai et al., 2002; Gong et al., 2018) antibodies. The gene discussed is CD274; the disease is cancer.